Skip to main content
main-content

08.10.2019 | Research Paper | Ausgabe 6/2019

Clinical & Experimental Metastasis 6/2019

Breast cancer cells expressing cancer-associated sialyl-Tn antigen have less capacity to develop osteolytic lesions in a mouse model of skeletal colonization

Zeitschrift:
Clinical & Experimental Metastasis > Ausgabe 6/2019
Autoren:
Ryo Fujita, Hiroki Hamano, Yusuke Kameda, Ryuta Arai, Tomohiro Shimizu, Masahiro Ota, Dai Sato, Hideyuki Kobayashi, Norimasa Iwasaki, Masahiko Takahata
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s10585-019-09999-6) contains supplementary material, which is available to authorized users.
Ryo Fujita and Hiroki Hamano have contributed equally to this article.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Breast cancer is one of the most prevalent malignancies in women, and approximately 75–80% of patients with advanced breast cancer develop bone metastasis. Expression of the cancer-associated carbohydrate antigen sialyl-Tn (STn) in breast cancer is associated with a poor prognosis; however, involvement of STn in the development of metastatic bone lesions remains unclear. We investigated whether STn expression on breast cancer cells influences intraosseous tumor growth and bone response in mice models of skeletal colonization. STn-positive (STn+) breast cancer cells were generated by stable transfection of an expression vector encoding ST6GaLNAc I into the breast cancer cell line MDA-MB-231. Parental MDA-MB-231 cells not expressing STn antigen were used as STn-negative (STn) breast cancer cells. Contrary to expectations, STn expression attenuated the development of destructive bone lesions in the in vivo mice models. An in vitro study demonstrated that STn expression impaired adhesion of MDA-MB-231cells to bone marrow stromal cells. This finding in vitro was also confirmed by another breast cancer cell line MCF-7. Cell adhesion to fibronectin and type I collagen was also impaired in STn+ MDA-MB-231 cells compared to that in STn MDA-MB-231 cells, suggesting integrin dysfunction. Given that the integrin β1 subunit is the main carrier of the STn epitope, it is likely that changes in glycan structure impaired the adhesive capacity of β1 integrin in the bone environment, leading to attenuation of tumor cell engraftment. In conclusion, breast cancer cells expressing STn antigen had less capacity for skeletal colonization, possibly due to impaired adhesive capability.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1—Immunocytochemistry and gene expression analysis to confirm the expression of STn on MCF-7 breast cancer cells. (a) Immunofluorescence microscopy confirmed that ST6GalNAc I -expressing cells expressed the STn antigen on the cell surface of MCF-7 cells. (b) STn detection by flow cytometry. The presence of the STn antigen was revealed using STn mAb (black lines) and negative controls (dotted lines, secondary antibodies only). (c) Expression of the ST6GalNAc I gene was examined by quantitative PCR. Abbreviations: STn, sialyl-Tn; mAb, monoclonal antibody. RNAi, ST6GalNAc I knockdown clones from STn+ MCF-7 cells.(JPEG 781 kb)
10585_2019_9999_MOESM1_ESM.jpg
Supplementary material 2 (DOCX 13 kb)
10585_2019_9999_MOESM2_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 6/2019

Clinical & Experimental Metastasis 6/2019 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise